Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with nonalcoholic fatty liver disease (NAFLD)

Yoneda, Masato; Mawatari, Hironori; Fujita, Koji; Endo, Hideki; Iida, Hiroshi; Nozaki, Yuichi; Yonemitsu, Kenji; Higurashi, Takuma; Takahashi, Hirokazu; Kobayashi, Noritoshi; Kohno, Hiroyuki; Abe, Yasunobu; Inamori, Masahiko; Kubota, Kensuke; Saito, Satoru; Tamano, Masaya; Hiraishi, Hideyuki; Maeyama, Shiro; Yamaguchi, Naotaka; Togo, Shinji; Nakajima, Atsushi

doi:10.1016/j.dld.2007.10.019

Cited by 381 publications

(327 citation statements)

References 36 publications

Supporting

Mentioning

293

Contrasting

Unclassified

Order By: Relevance

“…Studies using the Fibroscan® system to determine cut-off stiffness values for diagnosing cirrhosis have reported varying thresholds depending on the cause of liver cirrhosis (Castéra et al, 2005;Nguyen-Khac E, 2007;GanneCarrié et al, 2006). Cut-off values of 12.5 kPa have been reported for the diagnosis of viral hepatitis C cirrhosis (Castéra et al, 2005), while alcoholic liver disease and non-alcoholic fatty liver disease have been reported to show significantly higher cut-offs of 19 -21.5 kPa (NguyenKhac E, 2007;Ganne-Carrié et al, 2006) and 17.5 kPa (Yoneda et al, 2008), respectively.…”

Section: Resultsmentioning

confidence: 99%

“…However, such empirical correlations between the degree of liver fibrosis and Fibroscan® measurements may not hold for different liver conditions, such as Hepatitis C and non-alcoholic fatty liver disease (Yoneda et al, 2008;Ziol et al, 2005). To replace LNB as the sole diagnostic technique for a variety for liver diseases, it is clear that the absolute accuracy of an elastography ultrasound system must be determined, so that clinicians can have confidence that the measured values accurately reflect the underlying pathology.…”

Section: Introductionmentioning

confidence: 99%

“…These conditions, together with alcoholic liver disease and non-alcoholic fatty liver disease, among others, may lead to the development of extensive fibrosis or cirrhosis of the liver, with the latter associated with an increased risk of morbidity and mortality (Rojkind, 2001;Nahon et al, 2008;Yoneda et al, 2008;Zhou and Lu, 2009). The Fibroscan® system (Echosens, France) utilizes transient elastography to determine the mechanical status of the liver through the application of 1-D reflective mode transient elastography and has emerged as a means of estimating the extent of fibrosis in the liver in a clinical setting via a direct measurement of the liver stiffness.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Assessment of the accuracy of an ultrasound elastography liver scanning system using a PVA-cryogel phantom with optimal acoustic and mechanical properties

Cournane¹,

Cannon²,

Browne³

et al. 2010

Phys. Med. Biol.

View full text Add to dashboard Cite

The accuracy of a transient elastography liver-scanning ultrasound system was assessed using a novel application of PVA-cryogel as a tissue-mimicking material with acoustic and shear elasticity properties optimized to best represent those of liver tissue. Although the liver-scanning system has been shown to offer a safer alternative for diagnosing liver cirrhosis through stiffness measurement, as compared to the liver needle biopsy exam, the scanner's accuracy has not been fully established. The Young's elastic modulus values of 5-6wt% PVA-cryogel phantoms, also containing glycerol and 0.3μm Al 2 O 3 and 3μm Al 2 O 3 , were measured using a 'gold standard' mechanical testing technique and transient elastography. The mechanically measured values and acoustic velocities of the phantoms ranged between 1.6-16.1kPa and 1540-1570m/s, respectively, mimicking those observed in liver tissue. The values reported by the transient elastography system overestimated the Young's elastic modulus values representative of the progressive stages of liver fibrosis by up to 32%. These results were attributed to the relative rather than absolute nature of the measurement arising from the singlepoint acoustic velocity calibration of the system, rendering the measurements critically dependent on the speed of sound of the sample under investigation. Given the wide range of acoustic velocities which exist in the liver, spanning healthy tissue to cirrhotic pathology, coupled with the system's assumption that the liver is approximately elastic when it is rather highly viscoelastic, care should be exercised when interpreting the results from this system in patient groups.2

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Assessment of the accuracy of an ultrasound elastography liver scanning system using a PVA-cryogel phantom with optimal acoustic and mechanical properties

Cournane¹,

Cannon²,

Browne³

et al. 2010

Phys. Med. Biol.

View full text Add to dashboard Cite

show abstract

“…Unfortunately, no imaging modality is useful for the diagnosis of NASH. US-based transient elastography or FibroScan, which measures liver stiffness noninvasively, has shown promising results for assessing the severity of liver fibrosis [57,58].…”

Section: Imaging Modalitiesmentioning

confidence: 99%

Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis

et al. 2015

View full text Add to dashboard Cite

Nonalcoholic fatty liver disease (NAFLD) is currently the most common cause of chronic liver disease in industrialized countries worldwide, and has become a serious public health issue not only in Western countries but also in many Asian countries including Japan. Within the wide spectrum of NAFLD, nonalcoholic steatohepatitis (NASH) is a progressive form of disease, which often develops into liver cirrhosis and increases the risk of hepatocellular carcinoma. In turn, a large proportion of NAFLD/NASH is the liver manifestation of metabolic syndrome, suggesting that NAFLD/NASH plays a key role in the pathogenesis of systemic atherosclerotic diseases. Currently, a definite diagnosis of NASH requires liver biopsy, though various noninvasive measures are under development. The mainstays of prevention and treatment of NAFLD/NASH include dietary restriction and exercise; however, pharmacological approaches are often necessary.Currently, vitamin E and thiazolidinedione derivatives are the most evidence-based therapeutic options, although the clinical evidence for long-term efficacy and safety is limited. This practice guideline for NAFLD/NASH, established by the Japanese Society of Gastroenterology in cooperation with The Japan Society of Hepatology, covers lines of clinical evidence reported internationally in the period starting from 1983 to January 2012, and each clinical question was evaluated using the GRADE system. Based on the primary release of the full version in Japanese, this English summary provides the core essentials of this clinical practice guideline comprising the definition, diagnosis, and current therapeutic recommendations for NAFLD/NASH in Japan.

show abstract

“…Likewise, transient elastography is limited by reduced performance in obese patients, and interference by concomitant inflammation and steatosis [10,11]. These concerns about reproducibility and over-or under-estimation of fibrosis stage are even more problematic for non-CHC diseases such as CHB [12,13] and NAFLD [14,15].…”

Section: Introductionmentioning

confidence: 99%

FibroGENE: A gene-based model for staging liver fibrosis

Eslam

Hashem

Romero–Gómez

et al. 2016

Journal of Hepatology

View full text Add to dashboard Cite

: A gene-based model for staging liver fibrosis, Journal of Hepatology (2015), doi: http://dx.doi.org/10. 1016/j.jhep.2015.11.008 This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. Background& aim: The extent of liver fibrosis predicts long term outcomes, and hence impacts

show abstract

Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with nonalcoholic fatty liver disease (NAFLD)

Cited by 381 publications

References 36 publications

Assessment of the accuracy of an ultrasound elastography liver scanning system using a PVA-cryogel phantom with optimal acoustic and mechanical properties

Assessment of the accuracy of an ultrasound elastography liver scanning system using a PVA-cryogel phantom with optimal acoustic and mechanical properties

Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis

FibroGENE: A gene-based model for staging liver fibrosis

Contact Info

Product

Resources

About